Skip to Main Content

Author Details

Michael Schotsaert
Icahn School of Medicine at Mount Sinai
2008
96
34
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37938158Experimental co-infection of calves with SARS-CoV-2 Delta and Omicron variants of concern.Emerg Microbes Infect2024
37867244Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity.Small2024
36711479A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice.Res Sq2023
38077015Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.Res Sq2023
38076343SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels.Nat Cardiovasc Res2023
37520727Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia.iScience2023
37581936Rescue of alveolar wall liquid secretion blocks fatal lung injury due to influenza-staphylococcal coinfection.J Clin Invest2023
37991921Protocol for establishing primary human lung organoid-derived air-liquid interface cultures from cryopreserved human lung tissue.STAR Protoc2023
37645908SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels.bioRxiv2023
37872315Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19.Nat Immunol2023
37600776Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia.Front Immunol2023
37425792Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian Hamsters.bioRxiv2023
37020354Progress in vaccine development for infectious diseases-a Keystone Symposia report.Ann N Y Acad Sci2023
37386041Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.NPJ Vaccines2023
37034597Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia.bioRxiv2023
34668780SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.J Virol2022
35351865Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies.Cell Death Dis2022
35719387Longitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination.Front Genet2022
35784650Development of an HIV reporter virus that identifies latently infected CD4<sup>+</sup> T cells.Cell Rep Methods2022
35658571Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.Microbiol Spectr2022
36426358RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine.Front Immunol2022
36561187Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.bioRxiv2022
36044897Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.Med2022
36059549Editorial: Pandemic influenza vaccine approaches: Current status and future directions.Front Immunol2022
35128980Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models.Toxicol Pathol2022
35247306Limited extent and consequences of pancreatic SARS-CoV-2 infection.Cell Rep2022
35025969Advances and gaps in SARS-CoV-2 infection models.PLoS Pathog2022
35169796The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters.bioRxiv2022
34957381ACE2-IgG1 fusions with improved <i>in vitro</i> and <i>in vivo</i> activity against SARS-CoV-2.iScience2022
33464672Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.Angew Chem Int Ed Engl2021
33795830Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience.Mod Pathol2021
33495306Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Science2021
33882122IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization.J Exp Med2021
33653892Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.mBio2021
33790474TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.Nat Immunol2021
33619480A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.bioRxiv2021
33619476COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.Res Sq2021
33920517Replication-Competent οNS1 Influenza A Viruses Expressing Reporter Genes.Viruses2021
33532796The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.medRxiv2021
33836156TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.Cell2021
33501468The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera.medRxiv2021
34981044The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters.Res Sq2021
34707161A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.Nat Commun2021
34671037COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.Nat Commun2021
34401874Prophylactic Protection Against Respiratory Viruses Conferred by a Prototype Live Attenuated Influenza Virus Vaccine.Res Sq2021
34517409Virus-induced senescence is a driver and therapeutic target in COVID-19.Nature2021
34603303A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.Front Immunol2021
34773048Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.Sci Rep2021
34623911Tox2 is required for the maintenance of GC T<sub>FH</sub> cells and the generation of memory T<sub>FH</sub> cells.Sci Adv2021
34620951Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device.Sci Rep2021
  • 1 - 50 of 96

Recommended Authors

Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 20
Yale University School of Medicine
Career Start Year 2017
Number of shared co-authors 0
University of North Carolina at Chapel Hill
Career Start Year 2014
Number of shared co-authors 10
Yale School of Medicine
Career Start Year 2014
Number of shared co-authors 0
Duke University School of Medicine
Career Start Year 2012
Number of shared co-authors 3
University of Texas Medical Branch
Career Start Year 2012
Number of shared co-authors 2
University of Maryland School of Medicine
Career Start Year 2011
Number of shared co-authors 2
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 37
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 2009
Number of shared co-authors 5
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 10
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 4
FluGen Inc.
Career Start Year 2007
Number of shared co-authors 1
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 20
Centers for Disease Control and Prevention
Career Start Year 2006
Number of shared co-authors 0
University of California san francisco
Career Start Year 2006
Number of shared co-authors 17
NYU Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 6
University of North Carolina at Chapel Hill
Career Start Year 2003
Number of shared co-authors 11
University of Iowa
Career Start Year 2002
Number of shared co-authors 28
Center for Infectious Diseases Research, Walter Reed Army Institute of Research
Career Start Year 2002
Number of shared co-authors 2
Korea University College of Medicine
Career Start Year 2001
Number of shared co-authors 10
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 9
Infectious Disease Clinical Research Program, Uniformed Services University
Career Start Year 2000
Number of shared co-authors 1
University of Texas Medical Branch
Career Start Year 1997
Number of shared co-authors 7
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 36
Saint Louis University School of Medicine
Career Start Year 1992
Number of shared co-authors 4
Center for Vaccines and Immunology, University of Georgia
Career Start Year 1991
Number of shared co-authors 11
Centers for Disease Control and Prevention.
Career Start Year 1989
Number of shared co-authors 19
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 4
Mayo Clinic Vaccine Research Group
Career Start Year 1985
Number of shared co-authors 3
University of North Carolina
Career Start Year 1981
Number of shared co-authors 15

Collaborators

Icahn School of Medicine at Mount Sinai
Co-authored papers 59
Icahn School of Medicine at Mount Sinai New York
Co-authored papers 35
University of Maryland
Co-authored papers 12
Icahn School of Medicine at Mount Sinai
Co-authored papers 10
Icahn School of Medicine at Mount Sinai
Co-authored papers 9
Icahn School of Medicine at Mount Sinai
Co-authored papers 9
University of Geneva
Co-authored papers 9
College of Veterinary Medicine, Kansas State University
Co-authored papers 7
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 7
Icahn School of Medicine at Mount Sinai
Co-authored papers 6
Icahn School of Medicine at Mount Sinaigrid.59734.3c
Co-authored papers 6
Icahn School of Medicine at Mount Sinai
Co-authored papers 6
Icahn School of Medicine at Mount Sinai
Co-authored papers 6
Icahn School of Medicine at Mount Sinai
Co-authored papers 5
Icahn School of Medicine at Mount Sinai
Co-authored papers 5
Icahn School of Medicine at Mount Sinai
Co-authored papers 5
College of Veterinary Medicine, Kansas State University
Co-authored papers 4
The Scripps Research Institute
Co-authored papers 4
Michigan State University College of Human Medicine
Co-authored papers 4
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Washington University School of Medicine
Co-authored papers 3
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 3
College of Veterinary Medicine, Kansas State University
Co-authored papers 3
Texas Biomedical Research Institute
Co-authored papers 3
Icahn School of Medicine at Mount Sinai
Co-authored papers 3
The Scripps Research Institute, USA The Skaggs Institute for Chemical Biology
Co-authored papers 3
University of California San Francisco
Co-authored papers 3
The Scripps Research Institute
Co-authored papers 2
Co-authored papers 2
Center for Epigenetics and Metabolism, University of California irvine
Co-authored papers 2